Table 1.

Participant characteristics

VariableN = 183
n%
Sex   
Male 94 51 
Female 89 49 
Genotype   
HbSS/HbSβ0-thalassemia 123 67 
HbSC/HbSβ+thalassemia/other 60 33 
Transfer gap (mo)   
<2 135 74 
≥2 to <6 26 14 
≥6 22 12 
Insurance payor   
Public 157 86 
Private 11 
Not insured 15 
Hydroxyurea utilization   
Ever used 137 75 
Never used 46 25 
Chronic transfusion history   
Ever treated 61 67 
Never treated 122 33 
VariableN = 183
n%
Sex   
Male 94 51 
Female 89 49 
Genotype   
HbSS/HbSβ0-thalassemia 123 67 
HbSC/HbSβ+thalassemia/other 60 33 
Transfer gap (mo)   
<2 135 74 
≥2 to <6 26 14 
≥6 22 12 
Insurance payor   
Public 157 86 
Private 11 
Not insured 15 
Hydroxyurea utilization   
Ever used 137 75 
Never used 46 25 
Chronic transfusion history   
Ever treated 61 67 
Never treated 122 33 
MedianIQRMin, max
Adult patient follow-up time (y) 5.0 3.0-7.0 1.0-9.0 
Age at transfer (y) 18.2 18.0-18.5 17.1-19.4 
Pediatric inpatient visits (last 2 y) 0-2 0-15 
Pediatric ED visits (last 2 y) 0-0 0-8 
Pediatric outpatient visits (last 2 y) 20 12-32 3-198 
Transfer gap (mo) 1.4 1.0-2.2 0-65 
Adult inpatient encounters per year 0.3 0.2-1.0 0.1-10.7 
Adult ED encounters per year 0.5 0.3-1.4 0.1-25.0 
Adult outpatient encounters per year 5.0 2.4-8.4 0.3-36.9 
MedianIQRMin, max
Adult patient follow-up time (y) 5.0 3.0-7.0 1.0-9.0 
Age at transfer (y) 18.2 18.0-18.5 17.1-19.4 
Pediatric inpatient visits (last 2 y) 0-2 0-15 
Pediatric ED visits (last 2 y) 0-0 0-8 
Pediatric outpatient visits (last 2 y) 20 12-32 3-198 
Transfer gap (mo) 1.4 1.0-2.2 0-65 
Adult inpatient encounters per year 0.3 0.2-1.0 0.1-10.7 
Adult ED encounters per year 0.5 0.3-1.4 0.1-25.0 
Adult outpatient encounters per year 5.0 2.4-8.4 0.3-36.9 

ED, emergency department; max, minimum; min, maximum.

or Create an Account

Close Modal
Close Modal